The randomized phase II trial PACE tested palbociclib/avelumab/fulvestrant combination for HR + /HER2- metastatic BC previously progressed on CDK4/6 inhibitor + aromatase dual therapy. The gene discussed is ERBB2; the disease is breast cancer.